Silexion Therapeutics (SLXN) Competitors

Tempest Therapeutics (NASDAQ:TPST) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Which has more risk & volatility, TPST or SLXN?

Tempest Therapeutics has a beta of -2.34, indicating that its share price is 334% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.

Which has preferable earnings & valuation, TPST or SLXN?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$29.49M	-$19.51	-0.36
Silexion Therapeutics	N/A	N/A	$260K	N/A	N/A

Do insiders and institutionals hold more shares of TPST or SLXN?

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by insiders. Comparatively, 33.0% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor TPST or SLXN?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.93 beat Tempest Therapeutics' score of -0.22 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is TPST or SLXN more profitable?

Silexion Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-187.44%	-82.61%
Silexion Therapeutics	N/A	N/A	-249.43%

Does the MarketBeat Community prefer TPST or SLXN?

Tempest Therapeutics received 100 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Silexion Therapeutics an outperform vote while only 65.38% of users gave Tempest Therapeutics an outperform vote.

Company	Underperform	Outperform
Tempest Therapeutics	Outperform Votes 102 65.38%	Underperform Votes 54 34.62%
Silexion Therapeutics	Outperform Votes 2 100.00%	Underperform Votes No Votes

Do analysts recommend TPST or SLXN?

Tempest Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 331.03%. Silexion Therapeutics has a consensus price target of $5.00, indicating a potential upside of 411.77%. Given Silexion Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silexion Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silexion Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Silexion Therapeutics beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.